UA75620C2 - Stable pharmaceutical form of paclitaxel and method for the preparation thereof - Google Patents
Stable pharmaceutical form of paclitaxel and method for the preparation thereof Download PDFInfo
- Publication number
- UA75620C2 UA75620C2 UA2003055025A UA2003055025A UA75620C2 UA 75620 C2 UA75620 C2 UA 75620C2 UA 2003055025 A UA2003055025 A UA 2003055025A UA 2003055025 A UA2003055025 A UA 2003055025A UA 75620 C2 UA75620 C2 UA 75620C2
- Authority
- UA
- Ukraine
- Prior art keywords
- paclitaxel
- solvents
- mixture
- stable pharmaceutical
- solution
- Prior art date
Links
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 37
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 37
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 22
- 238000002360 preparation method Methods 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims abstract description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 9
- 238000000859 sublimation Methods 0.000 claims abstract description 9
- 230000008022 sublimation Effects 0.000 claims abstract description 9
- 230000036512 infertility Effects 0.000 claims abstract description 3
- 230000007935 neutral effect Effects 0.000 claims abstract description 3
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 45
- 238000004108 freeze drying Methods 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 238000001035 drying Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004809 Teflon Substances 0.000 description 4
- 229920006362 Teflon® Polymers 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003978 infusion fluid Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- -1 carboxyl anions Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000004045 soybean oil emulsion Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL343615A PL203300B1 (pl) | 2000-10-31 | 2000-10-31 | Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego |
| PCT/PL2001/000082 WO2002036582A1 (en) | 2000-10-31 | 2001-10-19 | Stable pharmaceutical form of an anticancer drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA75620C2 true UA75620C2 (en) | 2006-05-15 |
Family
ID=20077651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003055025A UA75620C2 (en) | 2000-10-31 | 2001-10-19 | Stable pharmaceutical form of paclitaxel and method for the preparation thereof |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1363892B1 (cs) |
| AU (1) | AU2002212863A1 (cs) |
| BG (1) | BG65985B1 (cs) |
| CZ (1) | CZ300836B6 (cs) |
| DE (1) | DE60122384T2 (cs) |
| HU (1) | HUP0303089A3 (cs) |
| LT (1) | LT5069B (cs) |
| PL (1) | PL203300B1 (cs) |
| RU (1) | RU2236227C1 (cs) |
| SI (1) | SI21138B (cs) |
| SK (1) | SK287850B6 (cs) |
| UA (1) | UA75620C2 (cs) |
| WO (1) | WO2002036582A1 (cs) |
| ZA (1) | ZA200303276B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL161372A0 (en) * | 2001-11-30 | 2004-09-27 | Bristol Myers Squibb Co | Crystalline solvates of paclitaxel |
| WO2005061474A1 (en) | 2003-12-12 | 2005-07-07 | Quiral Química Do Brasil | Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions |
| AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| WO2009007992A2 (en) * | 2007-04-20 | 2009-01-15 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition produced by microprecipitation |
| RU2370258C2 (ru) * | 2007-11-16 | 2009-10-20 | Закрытое Акционерное Общество "Биокад" | Фармацевтическая композиция для парентеральной доставки в форме лиофилизата и способ ее получения |
| CN110437179A (zh) * | 2019-08-22 | 2019-11-12 | 江苏红豆杉药业有限公司 | 一种紫杉醇单晶晶体及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| RU2136673C1 (ru) * | 1992-12-24 | 1999-09-10 | Бристоль-Мейерз Сквибб Компани | Фосфонооксиметиловые эфиры таксановых производных, промежуточные соединения, противоопухолевая фармацевтическая композиция, способ ингибирования роста опухоли у млекопитающих |
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| CA2163837C (en) * | 1994-12-13 | 1999-07-20 | Robert K. Perrone | Crystalline paclitaxel hydrates |
| FR2729666A1 (fr) * | 1995-01-25 | 1996-07-26 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r, 3s)- benzoylamino-2-hydroxy-3-phenylpropionate de 4,10-diacetoxy- 2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxo- tax-11-en-13alpha-yle |
| FR2740686B1 (fr) * | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
-
2000
- 2000-10-31 PL PL343615A patent/PL203300B1/pl not_active IP Right Cessation
-
2001
- 2001-10-19 UA UA2003055025A patent/UA75620C2/uk unknown
- 2001-10-19 SI SI200120060A patent/SI21138B/sl not_active IP Right Cessation
- 2001-10-19 WO PCT/PL2001/000082 patent/WO2002036582A1/en active IP Right Grant
- 2001-10-19 HU HU0303089A patent/HUP0303089A3/hu unknown
- 2001-10-19 EP EP01981204A patent/EP1363892B1/en not_active Expired - Lifetime
- 2001-10-19 DE DE60122384T patent/DE60122384T2/de not_active Expired - Lifetime
- 2001-10-19 CZ CZ20031421A patent/CZ300836B6/cs not_active IP Right Cessation
- 2001-10-19 AU AU2002212863A patent/AU2002212863A1/en not_active Abandoned
- 2001-10-19 RU RU2003116136/15A patent/RU2236227C1/ru not_active IP Right Cessation
- 2001-10-19 SK SK629-2003A patent/SK287850B6/sk not_active IP Right Cessation
-
2003
- 2003-04-25 BG BG107764A patent/BG65985B1/bg unknown
- 2003-04-29 ZA ZA200303276A patent/ZA200303276B/xx unknown
- 2003-05-05 LT LT2003031A patent/LT5069B/lt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SI21138A (sl) | 2003-08-31 |
| WO2002036582A1 (en) | 2002-05-10 |
| CZ300836B6 (cs) | 2009-08-19 |
| PL203300B1 (pl) | 2009-09-30 |
| CZ20031421A3 (cs) | 2004-06-16 |
| DE60122384T2 (de) | 2007-08-16 |
| AU2002212863A1 (en) | 2002-05-15 |
| SK6292003A3 (en) | 2004-08-03 |
| HK1060733A1 (en) | 2004-08-20 |
| BG65985B1 (bg) | 2010-08-31 |
| LT5069B (lt) | 2003-11-25 |
| SK287850B6 (sk) | 2012-01-04 |
| PL343615A1 (en) | 2002-05-06 |
| SI21138B (sl) | 2006-10-31 |
| ZA200303276B (en) | 2004-04-21 |
| EP1363892B1 (en) | 2006-08-16 |
| DE60122384D1 (de) | 2006-09-28 |
| HUP0303089A2 (hu) | 2003-12-29 |
| LT2003031A (en) | 2003-09-25 |
| RU2236227C1 (ru) | 2004-09-20 |
| EP1363892A1 (en) | 2003-11-26 |
| HUP0303089A3 (en) | 2005-02-28 |
| BG107764A (bg) | 2004-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007020085A2 (en) | Compositions containing taxane derivatives for intravenous injection | |
| WO2011049650A1 (en) | Docetaxel formulations with lipoic acid | |
| US9763880B2 (en) | Non-aqueous taxane formulations and methods of using the same | |
| FI86800C (fi) | Menetelmä injektoitavan, käyttövalmiin, steriilin, pyrogeenivapaan antrasykliiniglykosidiliuoksen valmistamiseksi | |
| CZ298581B6 (cs) | Farmaceuticky stabilní prípravek oxaliplatiny k parenterální aplikaci | |
| AU702519B2 (en) | Parenteral pharmaceutical compositions containing GF120918A | |
| WO2014013903A1 (ja) | タキサン系活性成分含有液体組成物、その製造方法及び液体製剤 | |
| UA75620C2 (en) | Stable pharmaceutical form of paclitaxel and method for the preparation thereof | |
| CN111465389B (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
| CN1723887A (zh) | 一种紫杉醇注射剂及其制备方法 | |
| CN100467024C (zh) | 氯诺昔康注射用组合物及其制备方法 | |
| WO2003099288A1 (fr) | Composition medicinale | |
| Kamat et al. | Formulation development of small and large volume injections | |
| HK1060733B (en) | Method for the production of a stable pharmaceutical form of paclitaxel | |
| TWI246927B (en) | One kind of concentrated emulsion containing Paclitaxel (taxane) | |
| HK40033919B (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
| HK40033919A (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
| HK1210665B (en) | Non-aqueous taxane nanodispersion formulations and methods of using the same | |
| MXPA97002473A (en) | Parenteral pharmaceutical compositions containing gf1209 | |
| WO2011047636A1 (zh) | 一种含有助溶剂的紫杉烷类药物溶液及其制备方法 |